Search Clinical Trials | Vanderbilt-Ingram Cancer Center

Filter By:
Search by Keyword:

Displaying 1 - 10 of 15

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer.

https://news.vumc.org/2023/09/12/study-finds-new-genetic-susceptibilities-for-colon-cancer/

Tue, 09/12/2023 - 12:00

Cancer_Epidemiology_Research_Program

Tom Wilemon

Locked

High-Resolution Specimen PET-CT Imaging for the Intraoperative Visualization of Resection Margins: An Exploratory Study

Miscellaneous

Disease Sites: Miscellaneous

Phase: I

Investigator: Topf, Michael

NCTID:

Protocol No: VICCHNP24616

Learn More

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

Miscellaneous

This trial is being conducted to evaluate the efficacy of Phasix Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.

Disease Sites: Miscellaneous

Phase: IV

Investigator: Pierce, Richard

NCTID: NCT03911700

Protocol No: VICCGI2281

Learn More

A Study of PHST001 in Advanced Solid Tumors

Miscellaneous

PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.

Disease Sites: Miscellaneous

Phase: I

Investigator: Davis, Elizabeth

NCTID: NCT06840886

Protocol No: VICCPHI24591

Learn More

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Miscellaneous

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.

Disease Sites: Miscellaneous

Phase: I

Investigator: Davis, Elizabeth

NCTID: NCT06561685

Protocol No: VICC-DTPHI24160

Learn More

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Miscellaneous

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Disease Sites: Miscellaneous

Phase: I

Investigator: Kennedy, Laura

NCTID: NCT06253871

Protocol No: VICCPHI24527

Learn More

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Miscellaneous

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.

Disease Sites: Miscellaneous

Phase: I/II

Investigator: Heumann, Thatcher

NCTID: NCT05523947

Protocol No: VICC-DTMDT24023

Learn More

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Miscellaneous

This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

Disease Sites: Miscellaneous

Phase: Early I

Investigator: Osmundson, Evan

NCTID: NCT05996432

Protocol No: VICC-EDMDT23195

Learn More

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Multiple Cancer Types

Disease Sites: Adrenocortical, Bladder, Breast, Cervical, Colon, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Gynecologic, Head/Neck, Kidney (Renal Cell), Liver, Lung, Miscellaneous, Non Small Cell, Ovarian, Pancreatic, Phase I, Prostate, Rectal, Urologic, Uterine

Phase: I/II

Investigator: Choe, Jennifer

NCTID: NCT04626635

Protocol No: VICC-DTPHI24031

Learn More